Inhibition of adenylate cyclase by tetraplatin.
In the investigation of effects of platinum-containing compounds on dopamine (DA)-activated adenylate cyclase system, tetraplatin and cisplatin were found to suppress the increase of enzyme activity by various activators. However, tetraplatin was a much more potent inhibitor than cisplatin, with its I50 values being 1/25, 1/45, and 1/130 that of cisplatin in the presence of DA/Gpp(NH)p, NaF/AlCl3, and forskolin/Gpp(NH)p respectively.
Ho
B T
BT
Department of Neuro-oncology, University of Texas MD Anderson Cancer Center 77030.
Huo
Y Y
YY
Lee
J H
JH
Levin
V A
VA
D000067956:Adenylyl Cyclase Inhibitors; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002945:Cisplatin / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects / Q000201:enzymology; D004298:Dopamine / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains
D000067956:Adenylyl Cyclase Inhibitors; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D002945:Cisplatin; C049777:ormaplatin; D004298:Dopamine